Telix Pharmaceuticals (ASX:TLX) Reports H1 2025 Financial Results
Telix Pharmaceuticals (ASX:TLX) reports a 63% revenue increase in H1 2025, emphasizing strong growth and strategic investments for future expansion.
Category: Healthcare
Artrya Limited (ASX:AYA) Receives FDA Clearance for Salix® Coronary Plaque Module
Artrya Limited (ASX:AYA) receives FDA clearance for Salix® Coronary Plaque module, expanding its U.S. commercial opportunities.
Telix Pharmaceuticals (ASX:TLX) Reports Strong H1 2025 Results
Telix Pharmaceuticals (ASX:TLX) reports a 63% revenue increase in H1 2025, maintaining strong financial and operational growth.
Monash IVF Group Limited (ASX:MVF) Completes Independent Review of Clinic Incidents
Monash IVF Group Limited (ASX:MVF) finalises independent review of Brisbane and Clayton incidents, enhancing patient safety measures.
Opthea Limited (ASX:OPT) Announces Phase 3 Results and Funding Settlement
Opthea Limited (ASX:OPT) reports negative Phase 3 trial results and settles its Development Funding Agreement, ensuring solvency and outlining future strategies.
CSL Limited (ASX:CSL) Announces FY2025 Performance and Strategic Initiatives
CSL Limited (ASX:CSL) reports a 5% revenue increase for FY2025 and announces strategic initiatives including a demerger and share buyback program.
Pro Medicus Limited (ASX:PME) Announces Full-Year Results
Pro Medicus Limited (ASX:PME) reports a 31.9% revenue increase and declares a final fully-franked dividend of 30c per share.
Neuren Pharmaceuticals (ASX:NEU) Reports Q2 2025 DAYBUE Sales Growth
Neuren Pharmaceuticals (ASX:NEU) reports a 14% increase in DAYBUE Q2 2025 sales, reaching US$96.1 million.
Lumos Diagnostics (ASX:LDX) Announces Q4 FY25 Financial Results and Major Distribution Agreement
Lumos Diagnostics (ASX:LDX) reports Q4 FY25 revenue of US$2.6M, secures major US distribution deal, and advances FebriDx CLIA waiver study.
PYC Therapeutics (ASX:PYC) Releases Q2 2025 Shareholder Update
PYC Therapeutics (ASX:PYC) updates shareholders on significant clinical progress and a strong financial position in Q2 2025.